Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled,Multi-center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

NCT00267202 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00267202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00267202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled,Multi-center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2005
Completion date
April 30, 2008
Enrollment
275 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic asthma